Nurix Therapeutics Inc
NRIX
Market Cap$1.43B
Close$
Share Statistics
| Market cap | $1.43 Billion |
|---|---|
| Enterprise Value | $1.41 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-2.65 |
| Beta | 2.22 |
| Outstanding Shares | 62,377,551 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -8.39 |
|---|---|
| PEG | -25.92 |
| Price to Sales | - |
| Price to Book Ratio | 1.38 |
| Enterprise Value to Revenue | 25.01 |
| Enterprise Value to EBIT | -7.29 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Nurix Therapeutics Inc
2,020 employeesNurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other ch...